^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    FMS kinase inhibitor

    Related drugs:
    5d
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Completed, Deciphera Pharmaceuticals, LLC | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Romvimza (vimseltinib)
    7d
    Targeting the DKK1/CSF1 Signaling Axis to Reprogram M2 Macrophages and Reverse Chemoresistance in Head and Neck Squamous Cell Carcinoma. (PubMed, Eur J Pharm Sci)
    This study underscores the dual role of CSF1 in regulating both tumor survival and M2 macrophage activation in HNSCC. Targeting the DKK1/CSF1 axis may represent a promising strategy to overcome chemoresistance by disrupting tumor-macrophage crosstalk and reprogramming the immunosuppressive microenvironment.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • DKK1 (dickkopf WNT signaling pathway inhibitor 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CSF1 (Colony stimulating factor 1) • IL10 (Interleukin 10)
    |
    cisplatin • Turalio (pexidartinib)
    7d
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    metformin • Romvimza (vimseltinib)
    8d
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Romvimza (vimseltinib)
    28d
    Osteosarcoma-on-a-chip model mimicking intra-tumoral heterogeneity to interrogate tumor-associated macrophage reprogramming for immunotherapeutics. (PubMed, Biomaterials)
    Additionally, we employed pexidartinib and tenalisib to evaluate TAMs reversal in the iTC-OS-on-a-chip model by selectively inhibiting CSF1R and PI3Kγ, respectively. TAMs reprogramming from tumor promoting M2 to tumor suppressing M1 phenotype is confirmed through gene expression analysis of M1 (CCR7, IL-1β, IL-6) and M2 (CD206, CD163, IL-10) macrophage markers, alongside quantification of secreted cytokines via ELISA assay. This advanced iTC-OS-on-a-chip model offers a robust platform for investigating OS-immune cell interactions, enabling pre-clinical evaluation of chemo/immunotherapeutics and improving the translational relevance in OS research.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • CD163 (CD163 Molecule) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • IL10 (Interleukin 10) • CCR7 (Chemokine (C-C motif) receptor 7) • CSF1R (Colony stimulating factor 1 receptor) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1)
    |
    Turalio (pexidartinib) • tenalisib (RP6530)
    2ms
    Microglial Inflammatory Response in the Glioblastoma Microenvironment in Preclinical Models. (PubMed, Mol Neurobiol)
    Microglia inhibition or depletion by treating organotypic cultures with minocycline or PLX3397 resulted in reduced levels of all the evaluated cytokines in the medium, confirming the role of microglia in the inflammatory microenvironment of glioblastoma. These findings provide valuable insights into how microglia interact with tumors and healthy cells in the tumor microenvironment, driving neuroinflammation and tumor cell dedifferentiation. This understanding could pave the way for the development of innovative therapies for glioblastoma.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • NES (Nestin)
    |
    Turalio (pexidartinib) • minocycline
    3ms
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    metformin • Romvimza (vimseltinib)
    3ms
    A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) (clinicaltrials.gov)
    P2, N=48, Recruiting, Deciphera Pharmaceuticals, LLC | N=36 --> 48
    Enrollment change
    |
    Romvimza (vimseltinib)
    3ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Romvimza (vimseltinib)
    5ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    Romvimza (vimseltinib)
    5ms
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    metformin • Romvimza (vimseltinib)
    5ms
    Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas (clinicaltrials.gov)
    P1, N=32, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Jan 2026 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • Romvimza (vimseltinib)